Fig. 4.

Mean change in WPAI score with upadacitinib. a Activity impairment. b Presenteeism. c Overall work impairment. d Absenteeism. *P ≤ 0.1 vs. placebo. **P ≤ 0.05 vs. placebo. ***P ≤ 0.01 vs. placebo. ^†P ≤ 0.1 vs. UPA 3 mg BID. Change in WPAI score for induction period used the mITT population and LOCF, and was analyzed using ANCOVA, adjusting for treatment, baseline disease severity, and baseline value. Change in WPAI score for maintenance period used the ITT population and OC, and was analyzed using ANCOVA, adjusting for treatment and baseline value. ANCOVA analysis of covariance; BID twice daily; ITT intent-to-treat; LOCF last observation carried forward; MCID minimum clinically important difference; mITT modified intent-to-treat; OC observed cases; QD once daily; UPA upadacitinib; WPAI Work Productivity and Activity Impairment questionnaire